Raynaud, digital ulcers and calcinosis in scleroderma

Reumatol Clin. 2012 Sep-Oct;8(5):270-7. doi: 10.1016/j.reuma.2012.02.006. Epub 2012 Jul 25.

Abstract

Raynaud, digital ulcers and calcinosis are frequent manifestations of patients with systemic sclerosis. Digital ulcers are seen in more than half of the patients with scleroderma. Hospitalizations, ischemic complications and impairment of hand function are frequently observed in patients with digital ulcers, especially if treatment is delayed. Rapid and intensive treatment escalation in patients with scleroderma and refractory Raynaud's phenomenon is one of the most effective preventive action available in order to avoid the development of digital ulcers and tissue loss.

Publication types

  • Review

MeSH terms

  • Bosentan
  • Calcinosis / drug therapy
  • Calcinosis / etiology*
  • Calcinosis / physiopathology
  • Cell Hypoxia
  • Combined Modality Therapy
  • Endothelin-1 / physiology
  • Endothelium, Vascular / pathology
  • Endothelium, Vascular / physiopathology
  • Fingers / blood supply
  • Fingers / pathology
  • Foot Ulcer / drug therapy
  • Foot Ulcer / etiology
  • Foot Ulcer / physiopathology
  • Foot Ulcer / surgery
  • Humans
  • Ischemia / drug therapy
  • Ischemia / etiology
  • Ischemia / physiopathology
  • Ischemia / prevention & control
  • Multicenter Studies as Topic
  • Platelet Aggregation
  • Platelet Aggregation Inhibitors / therapeutic use
  • Randomized Controlled Trials as Topic
  • Raynaud Disease / diagnosis
  • Raynaud Disease / drug therapy
  • Raynaud Disease / etiology*
  • Raynaud Disease / therapy
  • Scleroderma, Systemic / complications*
  • Scleroderma, Systemic / diagnosis
  • Scleroderma, Systemic / drug therapy
  • Scleroderma, Systemic / physiopathology
  • Skin Ulcer / drug therapy
  • Skin Ulcer / etiology*
  • Skin Ulcer / physiopathology
  • Skin Ulcer / surgery
  • Sulfonamides / therapeutic use
  • Thrombophilia / etiology
  • Thrombosis / etiology
  • Thrombosis / prevention & control
  • Toes / blood supply
  • Toes / pathology
  • Vasoconstriction / physiology
  • Vasodilator Agents / therapeutic use

Substances

  • Endothelin-1
  • Platelet Aggregation Inhibitors
  • Sulfonamides
  • Vasodilator Agents
  • Bosentan